Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257621 · ClinicalTrials.gov registry record · Phase 2
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
A Phase 2 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00257621 is a Phase 2 study that has completed, run by ViiV Healthcare. The registered enrollment target is 30 participants.
The verdict
NCT00257621, a Phase 2 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a proof of concept (POC) single arm study of GW640385, a protease inhibitor, in combination with RTV and 2 or more nucleoside reverse transcriptase inhibitors (NRTI) backbone. This study has a 48 week duration and is open to both treatment naive and experienced patients who are HIV positive. There are 3 intensive pharmacokinetic (PK) visits.
Interventions
- DRUG Ritonavir
- DRUG GW640385
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257621
The ClinicalTrials.gov registry entry for NCT00257621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ritonavir is the first listed.
NCT00257621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257621 about?
NCT00257621 is a clinical study titled "GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults". This is a proof of concept (POC) single arm study of GW640385, a protease inhibitor, in combination with RTV and 2 or more nucleoside reverse transcriptase inhibitors (NRTI) backbone. This study has a 48 week duration and is open to both treatment naive and experienced patients who are HIV positive....
What is the current status of trial NCT00257621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-10. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00257621?
The interventions under investigation include: Ritonavir (DRUG), GW640385 (DRUG).
Who is sponsoring clinical trial NCT00257621?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.